CCL2 and breast carcinoma: Through analysis of data obtained from reverse phase protein profiling in a previous study [32], we found that CCL2 treatment of MCF10CA1d breast cancer cells enhanced phosphorylation of MET receptors, which was reduced in CCR2 knockout cells (Supplemental Fig. 1).